Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Capital expenditure changed -100.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Operating margin changed +49760 basis points from the comparable as-filed period.
Operating income changed -41.5% from the comparable as-filed period.
Revenue changed +106.0% from the comparable as-filed period.
Gross margin changed -2309 basis points from the comparable as-filed period.
Cash & equivalents changed -48.0% from the comparable as-filed period.
Capex / revenue changed -4689 basis points from the comparable as-filed period.
Net debt changed +52.0% from the comparable as-filed period.
Research & development changed +139.6% from the comparable as-filed period.
Inventory / revenue changed -36974 basis points from the comparable as-filed period.
Trade receivables changed +92.2% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.